LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Closed

SectorHealthcare

168.66 -1.6

Overview

Share price change

24h

Current

Min

167.72

Max

174.52

Key metrics

By Trading Economics

Income

2.9M

56M

Sales

-27M

1B

P/E

Sector Avg

592.3

105.69

EPS

2.43

Profit margin

5.529

Employees

18,700

EBITDA

-23M

198M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.95% upside

Market Stats

By TradingEconomics

Market Cap

-487M

8.3B

Previous open

170.26

Previous close

168.66

News Sentiment

By Acuity

21%

79%

49 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lis 2025, 21:34 UTC

Earnings

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 lis 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 lis 2025, 23:42 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 lis 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q EPS 52c >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q Sales $22.6B >JBS

13 lis 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 lis 2025, 22:02 UTC

Earnings

Nu Holdings 3Q Net $783M >NU

13 lis 2025, 22:01 UTC

Earnings

Nu Holdings 3Q Rev $4.2B >NU

13 lis 2025, 21:51 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 lis 2025, 21:50 UTC

Earnings

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 lis 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 lis 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 lis 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 lis 2025, 21:33 UTC

Earnings

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 lis 2025, 21:31 UTC

Earnings

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q EPS 34c >FIGR

13 lis 2025, 21:23 UTC

Earnings

Intchains Group 3Q Rev $1.3M >ICG

13 lis 2025, 21:03 UTC

Earnings

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 lis 2025, 21:02 UTC

Earnings

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Rev $6.8B >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer Comparison

Price change

Charles River Laboratories International Inc Forecast

Price Target

By TipRanks

11.95% upside

12 Months Forecast

Average 192 USD  11.95%

High 225 USD

Low 165 USD

Based on 12 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

6

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

117.16 / 144.77Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

49 / 374 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat